EWTX Edgewise Therapeutics, Inc.
$39.17▼ -0.36%
Healthcare
Other
Pre-market
$39.15▼ -0.05%
Oct 27, 7:12 AM ET
Volume 1.01M
Avg Volume (10D) 1.41M
Key Metrics & Fundamentals
Market Cap
$4.25B
P/E Ratio
–
Div Yield
0.00%
52W Range
15.66 - 48.51
% vs 50 MA
-6.16%
% vs 200 MA
8.82%
RSI-14
46.5
MACD Histogram
+0.2600
Beta (1Y vs SPY)
1.22
Free Cash Flow
-$42.50M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$61.35M
COGS
–
Operating Exp
$61.94M
Operating Income
-$61.94M
EBIT
-$61.94M
Pretax Income
-$57.33M
Net Income
-$57.33M
EPS (Diluted)
-0.53
Price & Volume History
Loading chart…
Recent News
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
Business Wire · Oct 21, 2026 12:30 PM ET
Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?
Zacks · Oct 19, 2026 8:40 AM ET
William Blar Initiates Coverage on Edgewise Therapeutics With Outperform Rating
MT Newswires · Oct 16, 2026 7:27 AM ET
Does Edgewise Therapeutics’ (EWTX) HFpEF Expansion Quietly Redefine Its Core Cardiovascular Strategy?
Simply Wall St. · Oct 14, 2026 10:11 PM ET
Edgewise Therapeutics Doses First Patient in Trial of Investigational Heart Failure Drug
MT Newswires · Oct 8, 2026 8:52 AM ET
Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
PR Newswire · Oct 8, 2026 8:00 AM ET
Edgewise Therapeutics (EWTX) Sets EDG 7500 Focus Call, Is It Still 20% Below Fair Value?
Simply Wall St. · Oct 2, 2026 11:11 PM ET
Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?
Zacks · Oct 2, 2026 8:15 AM ET
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
PR Newswire · Oct 1, 2026 8:00 AM ET
Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says
MT Newswires · Sep 25, 2026 1:42 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See EWTX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.